- India Globalization Capital recently acquired exclusive patent rights for the use of low-dose THC as a potential therapeutic agent for Alzheimer’s disease
- No other publicly traded cannabis pharmaceutical company has a patent filing for a potential Alzheimer’s treatment
- Costs associated with Alzheimer’s disease top $236 billion in the U.S. and $600 billion globally
India Globalization Capital, Inc. (NYSE MKT: IGC), a Maryland-based company, is currently preparing four products for medical trials, including Hyalolex for the treatment of Alzheimer’s disease. Alzheimer’s is a fatal, progressive brain disease that slowly destroys memory and thinking.
Alzheimer’s is the leading cause of dementia and the third-leading cause of death in the U.S. Treatment outlooks have been bleak, as there is currently no cure, no way to prevent the disease, and no long-term treatment for the disease. However, India Globalization Capital may well improve the outlook for Alzheimer’s patients with a novel cannabis-based pharmaceutical therapy.
Read the full article
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer